BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 32883358)

  • 1. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
    Jarius S; Lechner C; Wendel EM; Baumann M; Breu M; Schimmel M; Karenfort M; Marina AD; Merkenschlager A; Thiels C; Blaschek A; Salandin M; Leiz S; Leypoldt F; Pschibul A; Hackenberg A; Hahn A; Syrbe S; Strautmanis J; Häusler M; Krieg P; Eisenkölbl A; Stoffels J; Eckenweiler M; Ayzenberg I; Haas J; Höftberger R; Kleiter I; Korporal-Kuhnke M; Ringelstein M; Ruprecht K; Siebert N; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; Rostásy K;
    J Neuroinflammation; 2020 Sep; 17(1):262. PubMed ID: 32883358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.
    Jarius S; Pellkofer H; Siebert N; Korporal-Kuhnke M; Hümmert MW; Ringelstein M; Rommer PS; Ayzenberg I; Ruprecht K; Klotz L; Asgari N; Zrzavy T; Höftberger R; Tobia R; Buttmann M; Fechner K; Schanda K; Weber M; Asseyer S; Haas J; Lechner C; Kleiter I; Aktas O; Trebst C; Rostasy K; Reindl M; Kümpfel T; Paul F; Wildemann B;
    J Neuroinflammation; 2020 Sep; 17(1):261. PubMed ID: 32883348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
    Jarius S; Paul F; Franciotta D; Ruprecht K; Ringelstein M; Bergamaschi R; Rommer P; Kleiter I; Stich O; Reuss R; Rauer S; Zettl UK; Wandinger KP; Melms A; Aktas O; Kristoferitsch W; Wildemann B
    J Neurol Sci; 2011 Jul; 306(1-2):82-90. PubMed ID: 21550068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
    Kornbluh AB; Campano VM; Har C; Dwivedi P; Suslovic W; Sepeta L; Kahn I
    Mult Scler Relat Disord; 2024 May; 85():105526. PubMed ID: 38489945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic CSF parameters and MRZ reaction help in differentiating MOG antibody-associated autoimmune disease versus multiple sclerosis.
    Vlad B; Reichen I; Neidhart S; Hilty M; Lekaditi D; Heuer C; Eisele A; Ziegler M; Reindl M; Lutterotti A; Regeniter A; Jelcic I
    Front Immunol; 2023; 14():1237149. PubMed ID: 37744325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.
    Loos J; Pfeuffer S; Pape K; Ruck T; Luessi F; Spreer A; Zipp F; Meuth SG; Bittner S
    J Neurol; 2020 Jun; 267(6):1632-1642. PubMed ID: 32055995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases.
    Baumann M; Hennes EM; Schanda K; Karenfort M; Kornek B; Seidl R; Diepold K; Lauffer H; Marquardt I; Strautmanis J; Syrbe S; Vieker S; Höftberger R; Reindl M; Rostásy K
    Mult Scler; 2016 Dec; 22(14):1821-1829. PubMed ID: 26869530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
    Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
    JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    Horellou P; Wang M; Keo V; Chrétien P; Serguera C; Waters P; Deiva K
    J Neuroimmunol; 2015 Dec; 289():1-7. PubMed ID: 26616865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.
    Baumann M; Sahin K; Lechner C; Hennes EM; Schanda K; Mader S; Karenfort M; Selch C; Häusler M; Eisenkölbl A; Salandin M; Gruber-Sedlmayr U; Blaschek A; Kraus V; Leiz S; Finsterwalder J; Gotwald T; Kuchukhidze G; Berger T; Reindl M; Rostásy K
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):265-72. PubMed ID: 25121570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.
    Jarius S; König FB; Metz I; Ruprecht K; Paul F; Brück W; Wildemann B
    J Neuroinflammation; 2017 Aug; 14(1):171. PubMed ID: 28851393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort.
    Veselaj K; Kamber N; Briner M; Friedli C; Diem L; Guse K; Miclea A; Wiest R; Wagner F; Grabe H; Abegg M; Horn MP; Bigi S; Chan A; Hoepner R; Salmen A
    CNS Neurosci Ther; 2021 Apr; 27(4):426-438. PubMed ID: 33047894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
    Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
    J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
    Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.